Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health

Bermingham, W.H., Ardern-Jones, Michael, Huissoon, A.P. and Krishna, M.T. (2021) Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health. British Journal of Dermatology, 185 (4), 838-839. (doi:10.1111/bjd.20495).

Record type: Letter

Text

chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health - Accepted Manuscript

Available under License University of Southampton Accepted Manuscript Licence.

Download (39kB)

More information

Accepted/In Press date: 15 May 2021

e-pub ahead of print date: 20 May 2021

Published date: October 2021

Additional Information: Funding Information: Conflicts of interest: M.R.A.J. has acted as a speaker, consultant or advisor for Regeneron, Sanofi, LEO Pharma, AbbVie and Pfizer; and has acted as an investigator for commercial clinical studies (unpaid) with AbbVie, Amgen and LEO Pharma. A.P.H. has received support for attending conferences from CSL and Biotest, and payment for educational speaking and writing from ALK, Octapharma and Shire. M.T.K. has received grants from FSA, MRC CiC, GCRF and NIHR for research outside the submitted work; has received funds from ALK Abello to attend an international conference; and is clinical lead for the national allergy accreditation programme (IQAS, the Royal College of Physicians), a co‐opted steering group member of the BRIT registry, and chair of the EDI working group for the British Society for Allergy and Clinical Immunology. Our department in Birmingham received an educational grant from Thermo Fisher, ALK Abello, MEDA and other pharmaceutical companies for annual PracticAllergy courses.

Learn more about Institute for Life Sciences research